The Conversation (0)
Chembio Diagnostics secured a $5.8 million order from Bio-Manguinhos/Fiocruz for test components and intermediate product of DPP HIV 1/2 Assay in Brazil.
Chembio Diagnostics (NASDAQ:CEMI) secured a $5.8 million order from Bio-Manguinhos/Fiocruz for test components and intermediate product of DPP HIV 1/2 Assay in Brazil.
As quoted in the press release:
Chembio further announced that it also has received GMP (Good Manufacturing Practices) certification for the Chembio New York manufacturing facility from Brazil’s health regulatory agency, Agência Nacional de Vigilância Sanitária (ANVISA), which certification was granted for Chembio in collaboration with Bio-Manguinhos/Fiocruz.
Bio-Manguinhos is a subsidiary of the Oswaldo Cruz Foundation (Fiocruz), which is responsible for the development and production of vaccines, diagnostics and biopharmaceuticals, primarily to meet the demands of Brazil’s national public health system.
John Sperzel, Chembio’s CEO, commented, “We commend the decision by Brazil’s Ministry of Health to purchase the high-quality DPP® HIV 1/2 Assay from Bio-Manguinhos, using both blood and oral fluid, for the country’s HIV testing programs. The use of rapid POC diagnostic tests, along with prevention and treatment, are essential elements of Brazil’s response to HIV incidence, and we are pleased to play an important role in the country’s effort to reduce HIV infection rates and identify patients who will benefit from antiretroviral treatment.”
Click here to read the full press release.
Source: globenewswire.com